454 related articles for article (PubMed ID: 21526945)
1. Current perspectives on echinocandin class drugs.
Perlin DS
Future Microbiol; 2011 Apr; 6(4):441-57. PubMed ID: 21526945
[TBL] [Abstract][Full Text] [Related]
2. Echinocandin antifungal drugs in fungal infections: a comparison.
Chen SC; Slavin MA; Sorrell TC
Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
[TBL] [Abstract][Full Text] [Related]
3. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
[No Abstract] [Full Text] [Related]
4. Echinocandin Resistance in Candida.
Perlin DS
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S612-7. PubMed ID: 26567278
[TBL] [Abstract][Full Text] [Related]
5. Echinocandin resistance in Candida species: mechanisms of reduced susceptibility and therapeutic approaches.
Beyda ND; Lewis RE; Garey KW
Ann Pharmacother; 2012; 46(7-8):1086-96. PubMed ID: 22811350
[TBL] [Abstract][Full Text] [Related]
6. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
Garcia-Effron G; Lee S; Park S; Cleary JD; Perlin DS
Antimicrob Agents Chemother; 2009 Sep; 53(9):3690-9. PubMed ID: 19546367
[TBL] [Abstract][Full Text] [Related]
7. Role of FKS Gene in the Susceptibility of Pathogenic Fungi to Echinocandins.
Hori Y; Shibuya K
Med Mycol J; 2018; 59(2):E31-E40. PubMed ID: 29848909
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous Mutational Frequency and
Shields RK; Kline EG; Healey KR; Kordalewska M; Perlin DS; Nguyen MH; Clancy CJ
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373796
[TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
10. [In vitro activity of anidulafungin. Comparison with the activity of other echinocandins].
Martín Mazuelos E; Rodríguez-Tudela JL
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():7-13. PubMed ID: 19572429
[TBL] [Abstract][Full Text] [Related]
11. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints.
Garcia-Effron G; Park S; Perlin DS
Antimicrob Agents Chemother; 2009 Jan; 53(1):112-22. PubMed ID: 18955538
[TBL] [Abstract][Full Text] [Related]
12. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
Zimbeck AJ; Iqbal N; Ahlquist AM; Farley MM; Harrison LH; Chiller T; Lockhart SR
Antimicrob Agents Chemother; 2010 Dec; 54(12):5042-7. PubMed ID: 20837754
[TBL] [Abstract][Full Text] [Related]
13. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
Perlin DS
Drugs; 2014 Sep; 74(14):1573-85. PubMed ID: 25255923
[TBL] [Abstract][Full Text] [Related]
14. Differential Aspergillus lentulus echinocandin susceptibilities are Fksp independent.
Staab JF; Kahn JN; Marr KA
Antimicrob Agents Chemother; 2010 Dec; 54(12):4992-8. PubMed ID: 20855747
[TBL] [Abstract][Full Text] [Related]
15. Fks1 and Fks2 are functionally redundant but differentially regulated in Candida glabrata: implications for echinocandin resistance.
Katiyar SK; Alastruey-Izquierdo A; Healey KR; Johnson ME; Perlin DS; Edlind TD
Antimicrob Agents Chemother; 2012 Dec; 56(12):6304-9. PubMed ID: 23027185
[TBL] [Abstract][Full Text] [Related]
16. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
[TBL] [Abstract][Full Text] [Related]
17. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
18. Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyr.
Staab JF; Neofytos D; Rhee P; Jiménez-Ortigosa C; Zhang SX; Perlin DS; Marr KA
Antimicrob Agents Chemother; 2014 Sep; 58(9):5421-7. PubMed ID: 24982083
[TBL] [Abstract][Full Text] [Related]
19.
Nunnally NS; Etienne KA; Angulo D; Lockhart SR; Berkow EL
Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31481447
[TBL] [Abstract][Full Text] [Related]
20. Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.
Lepak A; Castanheira M; Diekema D; Pfaller M; Andes D
Antimicrob Agents Chemother; 2012 Nov; 56(11):5875-82. PubMed ID: 22948870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
